GILD · News · 20260804N
Revenue Performance and Mix
GILEAD SCIENCES, INC. · 2026-08-04 · Importance 48 · Surprise 40 · No source text
Gilead’s second-quarter 2026 total revenue increased 10% year over year to $7.8 billion from $7.08 billion. Product sales excluding Veklury rose 10% year over year to $7.6 billion, while total product sales including Veklury increased 8%. HIV sales grew 12%, supported by Biktarvy, Descovy and PrEP, while Trodelvy and Livdelzi also contributed to growth; quarterly PrEP sales exceeded $1 billion for the first time.
Key facts
- Product sales excluding Veklury increased 10% year-over-year to $7.6 billion in Q2 2026. source
- Gilead's base business sales grew 10% year-over-year to $7.6 billion in Q2 2026. source
- Gilead reported total Q2 2026 revenue of $7.8 billion. source
- Gilead reported Q2 2026 product sales of $7.6 billion. source
- Odefsey sales in Europe were updated to $58 million for the three months ended June 30, 2026 (correcting prior $28 million). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +8.8% | Product sales excluding Veklury increased 10% year-over-year to $7.6 billion in Q2 2026. |